Picture of Anteris Technologies Global logo

AVR Anteris Technologies Global Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-15.23%
3m-35.42%
6m-51.04%
1yrn/a
Volume Change (%)
10d/3m-40.98%
Price vs... (%)
52w High-63.48%
50d MA-16.82%
200d MA-35.57%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-183.73%
Return on Equity-247.07%
Operating Margin-3389.1%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Anteris Technologies Global EPS forecast chart

Profile Summary

Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.

Directors

    Last Annual
    December 31st, 2024
    Last Interim
    March 31st, 2025
    Incorporated
    January 29th, 2024
    Public Since
    December 13th, 2024
    No. of Shareholders
    3,669
    No. of Employees
    136
    Sector
    Healthcare Equipment & Supplies
    Industry
    Healthcare
    Exchange
    us flag iconNASDAQ Global Market
    Shares in Issue
    36,062,087

    AVR Share Price Performance

    Upcoming Events for AVR

    Q2 2025 Anteris Technologies Global Corp Earnings Release

    Q3 2025 Anteris Technologies Global Corp Earnings Release

    Similar to AVR

    Picture of 908 Devices logo

    908 Devices

    us flag iconNASDAQ Global Market

    Picture of Alpha Teknova logo

    Alpha Teknova

    us flag iconNASDAQ Global Market

    Picture of AtriCure logo

    AtriCure

    us flag iconNASDAQ Global Market

    Picture of Beta Bionics logo

    Beta Bionics

    us flag iconNASDAQ Global Market

    Picture of Brainsway logo

    Brainsway

    us flag iconNASDAQ Global Market

    FAQ